PriceTargets.com logo

Cellectis - CLLS Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $7.00
  • Forecasted Upside: 266.49%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$1.91 As of 11/20/2024 01:00 AM ET
▼ -0.05 (-2.55%)

This chart shows the closing price for CLLS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Cellectis Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CLLS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CLLS

Analyst Price Target is $7.00
▲ +266.49% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Cellectis in the last 3 months. The average price target is $7.00, with a high forecast of $10.00 and a low forecast of $5.00. The average price target represents a 266.49% upside from the last price of $1.91.

This chart shows the closing price for CLLS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 3 contributing investment analysts is to buy stock in Cellectis. This rating has held steady since April 2023, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/30/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/24/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/22/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/5/2024BarclaysLower TargetOverweight ➝ Overweight$7.00 ➝ $5.00
6/12/2024OppenheimerLower TargetOutperform ➝ Outperform$11.00 ➝ $10.00
5/31/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$6.00 ➝ $6.00
11/1/2023JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$6.00
8/8/2023OppenheimerReiterated RatingOutperform ➝ Outperform$11.00
8/7/2023JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$6.00
4/5/2023CitigroupLower TargetBuy$24.00 ➝ $16.00
3/17/2023Bryan, Garnier & CoInitiated CoverageBuy$6.00
3/13/2023JMP SecuritiesReiterated RatingMarket Outperform$6.00
3/13/2023OppenheimerLower TargetOutperform$16.00 ➝ $13.00
1/19/2023JMP SecuritiesLower TargetMarket Outperform$11.00 ➝ $6.00
12/14/2022CitigroupLower Target$36.00 ➝ $24.00
8/18/2022CitigroupBoost Target$34.00 ➝ $36.00
5/24/2022The Goldman Sachs GroupLower TargetSell$3.00 ➝ $2.00
5/18/2022Robert W. BairdUpgradeNeutral ➝ Outperform$10.00
5/13/2022BarclaysLower Target$9.00 ➝ $7.00
1/6/2022Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$39.00 ➝ $16.00
12/14/2021JMP SecuritiesReiterated RatingBuy
12/14/2021Robert W. BairdReiterated RatingHold$10.00
12/8/2021JMP SecuritiesReiterated RatingBuy$20.00
11/30/2021JMP SecuritiesInitiated CoverageOutperform$20.00
11/8/2021William BlairDowngradeOutperform ➝ Market Perform
10/17/2021Robert W. BairdReiterated RatingHold$10.00
10/8/2021Robert W. BairdDowngradeOutperform ➝ Neutral$39.00 ➝ $10.00
8/20/2021JonestradingReiterated RatingBuy$30.00
6/3/2021OppenheimerInitiated CoverageBuy$33.00
6/1/2021William BlairReiterated RatingBuy
5/27/2021Robert W. BairdReiterated RatingBuy$39.00
5/4/2021GuggenheimReiterated RatingBuy ➝ Neutral
4/29/2021Robert W. BairdReiterated RatingBuy$39.00
4/28/2021GuggenheimDowngradeBuy ➝ Neutral
3/16/2021Robert W. BairdUpgradeNeutral ➝ Outperform$23.00 ➝ $39.00
3/8/2021William BlairReiterated RatingOutperform
11/18/2020William BlairReiterated RatingBuy
10/15/2020Robert W. BairdDowngradeOutperform ➝ Neutral
8/19/2020CitigroupUpgradeNeutral ➝ Buy$15.00 ➝ $32.00
8/6/2020OppenheimerReiterated RatingBuy$33.00
7/7/2020Robert W. BairdLower TargetOutperform$28.00 ➝ $21.00
5/11/2020Robert W. BairdInitiated CoverageOutperform$20.00
5/7/2020OppenheimerReiterated RatingBuy$35.00
3/6/2020CitigroupBoost TargetNeutral$14.00 ➝ $16.00
3/6/2020The Goldman Sachs GroupDowngradeNeutral ➝ Sell$15.00 ➝ $11.00
2/19/2020BTIG ResearchBoost TargetBuy$37.00 ➝ $39.00
1/13/2020William BlairReiterated RatingBuy
12/16/2019Nomura SecuritiesReiterated RatingBuy$73.00
(Data available from 11/21/2019 forward)

News Sentiment Rating

0.06 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/24/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/24/2024
  • 3 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/23/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/23/2024
  • 1 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
8/22/2024
  • 2 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2024
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2024
  • 1 very positive mentions
  • 16 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
11/20/2024

Current Sentiment

  • 1 very positive mentions
  • 16 positive mentions
  • 1 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Cellectis logo
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Read More

Today's Range

Now: $1.91
Low: $1.89
High: $1.93

50 Day Range

MA: $1.99
Low: $1.75
High: $2.40

52 Week Range

Now: $1.91
Low: $1.70
High: $3.77

Volume

26,155 shs

Average Volume

102,344 shs

Market Capitalization

$106.16 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.1

Frequently Asked Questions

What sell-side analysts currently cover shares of Cellectis?

The following equities research analysts have issued reports on Cellectis in the last year: Barclays PLC, JMP Securities, Oppenheimer Holdings Inc., and StockNews.com.
View the latest analyst ratings for CLLS.

What is the current price target for Cellectis?

0 Wall Street analysts have set twelve-month price targets for Cellectis in the last year. Their average twelve-month price target is $7.00, suggesting a possible upside of 266.5%. Oppenheimer Holdings Inc. has the highest price target set, predicting CLLS will reach $10.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $5.00 for Cellectis in the next year.
View the latest price targets for CLLS.

What is the current consensus analyst rating for Cellectis?

Cellectis currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CLLS will outperform the market and that investors should add to their positions of Cellectis.
View the latest ratings for CLLS.

What other companies compete with Cellectis?

Other companies that are similar to Cellectis include Alpha Teknova, Taysha Gene Therapies, Canopy Growth, Akebia Therapeutics and 4D Molecular Therapeutics. Learn More about companies similar to Cellectis.

How do I contact Cellectis' investor relations team?

Cellectis' physical mailing address is 8 RUE DE LA CROIX JARRY, PARIS I0, 75013. The biotechnology company's listed phone number is (318) 169-1600 and its investor relations email address is [email protected]. The official website for Cellectis is www.cellectis.com. Learn More about contacing Cellectis investor relations.